XXII 22nd Century Group, Inc.
Consumer DefensiveAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.02
P/S
0.01
EV/EBITDA
0.79
DCF Value
$-9.52
FCF Yield
-7969.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-36.7%
Operating Margin
-133.9%
Net Margin
-44.9%
ROE
-25.0%
ROA
-13.2%
ROIC
-52.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 null | $4.1M | $-3.3M | $— |
| Q4 null | $1.0M | $-2.8M | $— |
| FY null | $7.0M | $-5.1M | $— |
| Q3 null | $1.5M | $5.5M | $— |
Analyst Ratings
View AllConsensus
—
Target (Consensus)
$1,237.50
Target (Median)
$1,237.50
Target Range
$1,125.00 - $1,350.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Consumer Defensive
Industry
Tobacco
Country
US
Exchange
—
Beta
0.77
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.